Nexien BioPharma Inc (NXEN)

[Renegades17]

We're on the same page

Alain Bankier should be market savvy, so the lack of IR effort is surprising to me, particularly given the strong sector backdrop.

The best explanation I can come up with, other than them waiting for substantive news, is that they want to keep the price low for the permanent CEO. By doing so, the new CEO's options would strike at a lower price, which would make the compensation package more attractive. This would be particularly true given the current depressed stock price level after the selling pressure from share registration and warrant exercises.